STOCK TITAN

Arcutis Biotherapeutics, Inc. - ARQT STOCK NEWS

Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company based in Westlake Village, California, specializing in developing and commercializing treatments for dermatological diseases. Founded in 2016, Arcutis leverages recent advances in immunology and inflammation to create differentiated therapies targeting immune-mediated dermatological conditions.

Arcutis' lead product, ZORYVE (roflumilast) cream, is a topical treatment for plaque psoriasis and atopic dermatitis. The company has recently launched ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis. Both formulations utilize roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor that has shown significant improvement in clinical trials.

Arcutis is also advancing its pipeline with ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema, and ARQ-255 for alopecia areata. The company champions meaningful innovation to address the urgent needs of patients living with chronic, immune-mediated skin conditions, aiming to improve treatment options and patient outcomes.

In recent developments, Arcutis has been actively participating in industry conferences, securing strategic collaborations, and expanding its workforce. The company's financial health is robust, with a strong cash position bolstered by a recent public offering and a strategic licensing agreement in Japan. Arcutis continues to focus on long-term growth and innovation, with multiple ongoing clinical programs targeting various inflammatory dermatological conditions.

For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

Rhea-AI Summary

Arcutis Biotherapeutics (NASDAQ: ARQT) launched the Expose Psoriasis campaign during Psoriasis Action Month, focusing on the significant physical and emotional impact of plaque psoriasis. Aimed at empowering patients to communicate openly with healthcare providers, family, and friends, the campaign features expert dermatological advice and personal stories. It highlights the challenges of discussing psoriasis symptoms, particularly in sensitive areas, and the importance of addressing both physical and emotional well-being in treatment. The initiative also emphasizes the need for strong support networks for those affected.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
none
-
Rhea-AI Summary

Arcutis Biotherapeutics (Nasdaq: ARQT) announced the completion of enrollment for its INTEGUMENT-2 Phase 3 trial, evaluating roflumilast cream 0.15% for atopic dermatitis in individuals aged six and older. A total of 683 subjects were enrolled in this pivotal study, following the earlier completion of the INTEGUMENT-1 trial. Topline data from both trials is expected by the end of 2022, which could support a supplemental New Drug Application (sNDA) in 2023 if results are favorable. Atopic dermatitis affects approximately 26 million individuals in the U.S., highlighting a significant unmet medical need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
-
Rhea-AI Summary

Arcutis Biotherapeutics has launched Arcutis Cares, the first patient assistance program for its topical psoriasis treatment, ZORYVE (roflumilast) cream 0.3%. This initiative offers ZORYVE at no cost to financially eligible individuals who are uninsured or underinsured. The program is open to those aged 12 and older residing in the U.S. and needing ZORYVE for FDA-approved uses. Additionally, a savings card for individuals with commercial insurance allows for reduced out-of-pocket costs. Arcutis aims to enhance accessibility and affordability of its treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
none
Rhea-AI Summary

Arcutis Biotherapeutics has launched ZORYVE (roflumilast) cream 0.3%, the first topical PDE4 inhibitor for treating plaque psoriasis in patients aged 12 and older. This steroid-free cream rapidly clears plaques and alleviates itch, including in hard-to-treat areas. ZORYVE is available nationwide through pharmacies by prescription. The company emphasizes accessibility through responsible pricing and patient support programs, including Arcutis Cares™ for uninsured patients. FDA approval was granted on July 29, 2022, marking a significant milestone for Arcutis in immuno-dermatology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
-
Rhea-AI Summary

Arcutis Biotherapeutics has received FDA approval for ZORYVE™ (roflumilast) cream 0.3%, a steroid-free treatment for plaque psoriasis in individuals aged 12 and older. The company also reported positive topline results from a pivotal Phase 3 trial for roflumilast foam aimed at seborrheic dermatitis, with an NDA submission expected in Q1 2023. Arcutis completed enrollment in the INTEGUMENT-1 trial for atopic dermatitis and bolstered its balance sheet with over $285 million from recent financings. As of June 30, 2022, the company had cash resources of approximately $570 million to support product launches and pipeline development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
-
Rhea-AI Summary

Arcutis Biotherapeutics (Nasdaq: ARQT) announced the successful enrollment of 654 participants in the INTEGUMENT-1 Phase 3 trial for roflumilast cream, aimed at treating atopic dermatitis (AD) in adults and children. The trial continues with INTEGUMENT-2, with topline data expected by the end of 2022. If trials prove successful, the company anticipates filing for a supplemental New Drug Application in 2023. Atopic dermatitis affects around 26 million individuals in the U.S., underlying the significance of this potential treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.81%
Tags
Rhea-AI Summary

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the grant of 22,200 restricted stock units and options to purchase 44,500 shares to five new employees. These awards are part of the 2022 Inducement Plan and were approved by the Compensation Committee. Restricted stock units vest over four years, while stock options have a ten-year term with an exercise price of $22.25 per share, reflecting the stock's closing price on the grant date, July 27, 2022. This initiative aligns with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.81%
Tags
none
-
Rhea-AI Summary

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced a public offering of 7,500,000 shares at $20.00 per share, with expected proceeds of $150 million. The offering also includes a 30-day option for underwriters to purchase an additional 1,125,000 shares. Proceeds will fund the development and commercialization of its programs, including ZORYVE, along with general corporate purposes. The offering is set to close on August 5, 2022, and follows an effective shelf registration statement filed on February 1, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.9%
Tags
-
Rhea-AI Summary

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the commencement of an underwritten public offering of $150 million of its common stock, with all shares sold by the company. This offering is subject to market conditions, and there is no guarantee regarding its completion or terms. Furthermore, Arcutis plans to give underwriters a 30-day option to purchase an additional 15% of the shares. The offering will be made pursuant to an effective shelf registration statement filed with the SEC. Morgan Stanley, Cowen, and Guggenheim Securities will act as bookrunning managers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.9%
Tags
Rhea-AI Summary

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced FDA approval for ZORYVE (roflumilast) cream 0.3%, targeting plaque psoriasis treatment in patients aged 12 and older. This approval is significant as it addresses the needs of patients with immune-mediated dermatological conditions. The company aims to leverage its innovative development platform, focusing on unmet patient needs in dermatology. A conference call will discuss the FDA approval details and future plans for commercialization, highlighting Arcutis's commitment to advancing dermatological therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.49%
Tags
conferences fda approval

FAQ

What is the current stock price of Arcutis Biotherapeutics (ARQT)?

The current stock price of Arcutis Biotherapeutics (ARQT) is $14.99 as of December 20, 2024.

What is the market cap of Arcutis Biotherapeutics (ARQT)?

The market cap of Arcutis Biotherapeutics (ARQT) is approximately 1.8B.

What does Arcutis Biotherapeutics, Inc. specialize in?

Arcutis specializes in developing and commercializing treatments for dermatological diseases, focusing on immune-mediated conditions.

What are the main products of Arcutis Biotherapeutics?

Arcutis' main products include ZORYVE (roflumilast) cream for plaque psoriasis and atopic dermatitis, and ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis.

Where is Arcutis Biotherapeutics headquartered?

Arcutis Biotherapeutics is headquartered in Westlake Village, California.

When was Arcutis Biotherapeutics founded?

Arcutis Biotherapeutics was founded in 2016.

What is ZORYVE?

ZORYVE is a brand name for Arcutis' roflumilast cream and topical foam, used to treat plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

What is the mechanism of action for ZORYVE?

ZORYVE utilizes roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor, which helps reduce inflammation by regulating immune response mediators.

What are Arcutis' latest achievements?

Recent achievements include the successful launch of ZORYVE foam, strategic licensing agreements, and strong financial results from a public offering.

How is Arcutis ensuring long-term growth?

Arcutis ensures long-term growth through continuous innovation, expanding clinical programs, strategic collaborations, and robust financial management.

What are some of Arcutis' ongoing projects?

Ongoing projects include clinical programs for ARQ-252 for hand eczema, ARQ-255 for alopecia areata, and additional studies for topical roflumilast formulations.

Where can I get more information about Arcutis Biotherapeutics?

For more information, visit Arcutis' official website at www.arcutis.com or follow them on LinkedIn, Facebook, Instagram, and X.

Arcutis Biotherapeutics, Inc.

Nasdaq:ARQT

ARQT Rankings

ARQT Stock Data

1.80B
103.96M
2.15%
113.6%
21.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WESTLAKE VILLAGE